| Financier | Commitments |
|---|---|
| IDA Credit | 7.50 |
Guyana COVID-19 Emergency Response Project
Abstract*
To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health
preparedness in Guyana. Show More
Development Objective
To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health
preparedness in Guyana.
Key Details
Project Details
P175268
Closed
Federica Secci , Behnaz Bonyadian Dehkordi
Co-operative Republic of Guyana
October 30, 2020
(as of board presentation)
November 25, 2020
December 15, 2020
US$ 7.50 million
Ministry of Health
2021
US$ 7.50 million
N/A
May 22, 2024
March 31, 2024
TBD
BANK APPROVED
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | N/A |
| IDA Commitment | 7.50 |
| IBRD + IDA Commitment | 7.50 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 7.50 |
Summary Status of World Bank Financing (US$ Millions) as of February 28, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Dec 1, 2022 | IDA-68020 | Int Charges | 172.68 |
| Dec 1, 2022 | IDA-68020 | Int Charges | 14,915.56 |
| Jun 1, 2023 | IDA-68020 | Int Charges | 21,000.78 |
| Jun 8, 2023 | IDA-68020 | Loan Disb | 74,027.79 |
| Jun 12, 2023 | IDA-68020 | Loan Disb | 127,260.00 |
| Jun 12, 2023 | IDA-68020 | Loan Disb | 77,058.89 |
| Jun 12, 2023 | IDA-68020 | Loan Disb | 56,855.58 |
| Jun 1, 2023 | IDA-69750 | Int Charges | 4,669.71 |
| Jun 1, 2023 | IDA-69750 | Int Charges | 4,669.71 |
| Dec 1, 2023 | IDA-68020 | Int Charges | 24,268.21 |
| Dec 1, 2023 | IDA-68020 | Int Charges | 24,268.21 |
| Nov 8, 2023 | IDA-69750 | Loan Disb | 150,000.00 |
| Dec 13, 2023 | IDA-69750 | Loan Disb | 749,984.00 |
| Dec 1, 2023 | IDA-69750 | Int Charges | 53.54 |
| Dec 1, 2023 | IDA-69750 | Int Charges | 53.54 |
| Dec 1, 2023 | IDA-69750 | Int Charges | 6,492.77 |
| Dec 1, 2023 | IDA-69750 | Int Charges | 6,492.77 |
| Dec 1, 2023 | IDA-68020 | Int Charges | 132.83 |
| Dec 1, 2023 | IDA-68020 | Int Charges | 132.83 |
| Jul 30, 2023 | IDA-68020 | Loan Disb | 1,158,462.90 |
| Jul 30, 2023 | IDA-68020 | Loan Disb | -1,158,462.90 |
| Sep 6, 2023 | IDA-68020 | Loan Disb | 81,999.99 |
| Feb 13, 2023 | IDA-68020 | Loan Disb | 49,189.42 |
| May 3, 2023 | IDA-68020 | Loan Disb | 8,562.10 |
| Jan 20, 2023 | IDA-69750 | Loan Disb | 1,500,000.00 |
| Jan 20, 2023 | IDA-68020 | Loan Disb | 31,726.21 |
| Mar 7, 2023 | IDA-68020 | Loan Disb | 84,840.00 |
| Mar 7, 2023 | IDA-68020 | Loan Disb | 138,368.40 |
| May 3, 2023 | IDA-68020 | Loan Disb | 187,869.61 |
| Feb 21, 2023 | IDA-68020 | Loan Disb | 93,934.80 |
| Feb 15, 2023 | IDA-69750 | Loan Disb | 287,472.00 |
| Jul 14, 2023 | IDA-68020 | Loan Disb | 322,859.60 |
| Feb 8, 2022 | IDA-68020 | Loan Disb | 195,368.84 |
| Feb 8, 2022 | IDA-68020 | Loan Disb | 1,081,652.90 |
| Feb 8, 2022 | IDA-68020 | Loan Disb | 26,821.00 |
| Sep 1, 2022 | IDA-68020 | Loan Disb | 51,224.00 |
| Dec 21, 2022 | IDA-68020 | Loan Disb | 8,702.59 |
| Sep 23, 2022 | IDA-68020 | Loan Disb | 759,453.40 |
| Oct 19, 2022 | IDA-68020 | Loan Disb | 60,821.62 |
| Dec 9, 2022 | IDA-68020 | Loan Disb | 476,473.00 |
| Dec 1, 2022 | IDA-68020 | Int Charges | 172.68 |
| Dec 1, 2022 | IDA-68020 | Int Charges | 14,915.56 |
| Feb 3, 2023 | IDA-68020 | Loan Disb | 31,311.60 |
| Apr 15, 2021 | IDA-68020 | Loan Disb | 688,138.00 |
| Dec 1, 2021 | IDA-68020 | Int Charges | 646.02 |
| Dec 1, 2021 | IDA-68020 | Int Charges | 646.02 |
| Dec 1, 2021 | IDA-68020 | Int Charges | 2,527.92 |
| Dec 1, 2021 | IDA-68020 | Int Charges | 2,527.92 |
| Jun 14, 2022 | IDA-68020 | Loan Disb | 39,946.00 |
| May 5, 2022 | IDA-68020 | Loan Disb | 563,364.56 |
| Mar 18, 2022 | IDA-68020 | Loan Disb | 121,014.61 |
| Apr 6, 2022 | IDA-68020 | Loan Disb | 5,176.72 |
| Jun 29, 2022 | IDA-68020 | Loan Disb | 991,848.75 |
| Mar 3, 2022 | IDA-68020 | Loan Disb | 160,856.02 |
| Jun 1, 2022 | IDA-68020 | Int Charges | 5,961.18 |
| Jun 1, 2022 | IDA-68020 | Int Charges | 5,961.18 |
| Jun 1, 2022 | IDA-68020 | Int Charges | 27.62 |
| Jun 1, 2022 | IDA-68020 | Int Charges | 27.62 |
| Jun 6, 2022 | IDA-68020 | Loan Disb | 241,284.00 |
| Jun 29, 2021 | IDA-69750 | Loan Commitment | 5,000,000.00 |
| Jun 4, 2024 | IDA-68020 | Int Charges | 25,171.00 |
| Jun 4, 2024 | IDA-68020 | Int Charges | 25,171.00 |
| Jun 4, 2024 | IDA-68020 | Int Charges | 319.12 |
| Jun 4, 2024 | IDA-68020 | Int Charges | 319.12 |
| Nov 25, 2020 | IDA-68020 | Loan Commitment | 7,500,000.00 |
| Jan 31, 2024 | IDA-69750 | Loan Disb | 96,400.00 |
| Feb 16, 2024 | IDA-68020 | Loan Disb | 42,930.00 |
| Mar 7, 2024 | IDA-69750 | Loan Disb | 34,470.78 |
| Apr 24, 2024 | IDA-68020 | Loan Disb | 211,295.70 |
| Jun 4, 2024 | IDA-69750 | Int Charges | 12,249.45 |
| Jun 4, 2024 | IDA-69750 | Int Charges | 12,249.45 |
| Jun 4, 2024 | IDA-69750 | Int Charges | 541.93 |
| Jun 4, 2024 | IDA-69750 | Int Charges | 541.93 |
| Feb 29, 2024 | IDA-69750 | Loan Disb | 294,496.00 |
| Jun 26, 2024 | IDA-69750 | Loan Disb | 295,117.30 |
| Jan 26, 2024 | IDA-69750 | Loan Disb | 138,803.10 |
| Oct 6, 2023 | IDA-69750 | Loan Disb | 331,600.00 |
| Aug 1, 2024 | IDA-68020 | Loan Disb | -56,313.75 |
| Jun 1, 2023 | IDA-68020 | Int Charges | 541.90 |
| Jun 1, 2023 | IDA-68020 | Int Charges | 541.90 |
| Jun 1, 2023 | IDA-68020 | Int Charges | 21,000.78 |
Ratings
IMPLEMENTATION RATINGS
| Name | Review | Date |
|---|---|---|
| Project Management | Satisfactory | 2024-10-16 |
| Monitoring and Evaluation | Satisfactory | 2024-10-16 |
| Overall Implementation Progress (IP) | Satisfactory | 2024-10-16 |
| Progress towards achievement of PDO | Satisfactory | 2024-10-16 |
| Procurement | Satisfactory | 2024-10-16 |
| Financial Management | Satisfactory | 2024-10-16 |
COMPLETION RATINGS
No data available.
INDEPENDENT EVALUATION RATINGS
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Suspected cases of COVID-19 investigated based on national guidelines Value 30.00 95.00 95.00 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment Patients diagnosed with COVID-19 that are treated per MOH approved protocol Value 95.00 100.00 98.00 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment Population vaccinated, which is included in the priority population targets defined in the national plan, total and disaggregated by gender Value 0.00 7.31 7.31 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents per MOH guidelines Value 1.00 6.00 7.00 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment Fully equipped ICU beds for treatment of COVID-19 cases Value 16.00 74.00 74.00 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment Risk communication campaigns for COVID-19 reaching targeted vulnerable groups, including those conducted in local languages Value 0.00 4.00 4.00 Date October 23, 2020 December 4, 2023 March 29, 2024 Comment Teams that support the COVID-19 vaccination campaign that include at least one female member (Percentage) Value 0.00 16.00 16.00 Date March 31, 2021 December 4, 2023 March 29, 2024 Comment Relevant staff who participated in the One Health training Value 0.00 20.00 100.00 Date March 31, 2021 December 4, 2023 March 29, 2024 Comment